Exportar registro bibliográfico


Metrics:

Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 (2015)


Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2020